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ABSTRACT
With >10,000,000 cancer survivors in the U.S. alone,
thelateeffectsofcancertreatmentareasignificantpub-
lic health issue. Over the past 15 years, much work has
been done that has led to an improvement in our under-
standing of the molecular mechanisms underlying the
development of normal tissue injury after cancer ther-
apy. In many cases, these injuries are characterized at
the histologic level by loss of parenchymal cells, exces-
sive fibrosis, and tissue atrophy. Among the many cyto-
kines involved in this process, transforming growth
factor (TGF)-1 is thought to play a pivotal role.
TGF-1 has a multitude of functions, including both
promoting the formation and inhibiting the breakdown
of connective tissue. It also inhibits epithelial cell prolif-
eration. TGF-1 is overexpressed at sites of injury after
radiation and chemotherapy. Thus, TGF-1 represents
a logical target for molecular therapies designed to pre-
vent or reduce normal tissue injury after cancer ther-
apy. Herein, the evidence supporting the critical role of
TGF-ß1 in the development of normal tissue injury af-
ter cancer therapy is reviewed and the results of recent
research aimed at preventing normal tissue injury by
targeting the TGF-ß1 pathway are presented. The On-
cologist 2010;15:350–359
INTRODUCTION
The tolerance of normal tissues and organs limits the
amount of chemotherapy and radiation therapy that can
be administered to a patient undergoing cancer treatment
[1, 2]. In many cases, these doses may be less than what
one would give under ideal circumstances in an effort to
control a tumor. Consequently, cure of the cancer might
not be achievable as a result of limitations imposed by
normal tissue tolerance. This is particularly true in cir-
cumstances requiring high doses of radiation for tumors lo-
cated within or adjacent to sensitive organs, such as the lung.
Traditionally, radiation oncologists have been forced to
deal with normal tissue tolerance by limiting the dose
and/or volume of tissue receiving radiation [3, 4]. With re-
cent advances in imaging technology, these dose–volume
relationships have received additional attention in an at-
tempttomorepreciselycorrelatedose,volume,andtherisk
for normal tissue injury [2]. These dose–volume relation-
Correspondence: Mitchell S. Anscher, M.D., VCU Medical Center, 401 College Street, P.O. Box 980058, Richmond, Virginia 23298-
0058, USA. Telephone: 804-828-7238; Fax: 804-828-7232; e-mail: manscher@mcvh-vcu.edu Received October 28, 2008; accepted
forpublicationApril29,2009;availableonlinewithoutsubscriptionthroughtheopenaccessoption.©AlphaMedPress1083-7159/2010/
$30.00/0 doi: 10.1634/theoncologist.2009-S101
The Oncologist
®
The Oncologist 2010;15:350–359 www.TheOncologist.comships, however, disregard the spatial distribution of dose
withinanorganandalsodonotaccountforbiologichetero-
geneity, genetic factors, and underlying comorbidities that
could impact an individual patient’s risk for treatment-
related complications.
Research over the past 15 years has led to a better un-
derstanding of the underlying molecular events responsible
for the development of normal tissue injury after cancer
therapy [5–8]. Of the many cytokines and growth factors
shown to contribute to the injury process, transforming
growth factor TGF)-1 is among the most important [9].
TGF-1belongstoafamilyofsecretedpolypeptidegrowth
factors subcategorized by function, including its three
mammalian isoforms (TGF-1, TGF-2, and TGF-3),
bone morphogenic proteins, activins, inhibins, and Mulle-
rian inhibiting substance [10, 11]. These proteins have im-
portant functions in both normal and disease-related
processes, such as cell growth, differentiation, migration,
adhesion, angiogenesis, immunity, extracellular matrix
synthesis, and epithelial–mesenchymal transition [12–15].
The TGF- family signals through a complex interactome
[16]involvingmultiplepathways.DisruptionoftheTGF-
signalingpathwayhasbeenimplicatedinthecellularacqui-
sitionofthehallmarksofmalignancy[17],thatis,failureto
respondtogrowthinhibitoryfactors,proliferationintheab-
senceofexogenouscues,invasion,metastasis,immortality,
loss of apoptosis, stimulation of angiogenesis, and evasion
of the immune system. Thus, under normal circumstances,
a number of genes coding for proteins in the TGF- signal-
ing pathway would be considered tumor suppressor genes.
In particular, most malignant cells are resistant to the
growthinhibitoryeffectsofTGF-throughavarietyofdif-
ferent mechanisms [18–20], and, in fact, TGF- has been
shown to stimulate the growth of malignant cell lines [21].
Thus, overexpression of TGF- within the tumor microen-
vironment could promote the local growth and metastatic
potential of many solid tumors [22]. That TGF-can function
as both a tumor suppressor and a tumor promotor, depending
on the environment in which it operates, points to the com-
plexity of the processes in which these proteins participate.
The most widely studied of this family of molecules is
TGF-1. A detailed discussion of its role in tumor promotion,
progression,andmetastasisisbeyondthescopeofthisreview.
Rather,herein,theroleofTGF-1innormaltissueinjury,par-
ticularly the lung, is reviewed and strategies to target TGF-1
to reduce the risk for normal tissue injury are discussed.
EVIDENCE FOR A ROLE FOR TGF-1 IN CHRONIC
NORMAL TISSUE INJURY AFTER CANCER THERAPY
Loss of parenchymal cells and an excess of fibrous tissue
often characterize late injury after cancer therapy (Fig. 1A,
1B). TGF-1 plays an important role in both normal and
abnormal wound healing [23, 24]. This cytokine is pro-
duced in a biologically inert form, bound to a latency asso-
ciate peptide to form the small latent TGF- complex,
which is secreted from cells and can be activated by several
methods, including through exposure to proteases, inte-
grins, and free radicals [25–30]. The small latent complex
may also be covalently bound to one of several latent
TGF- binding proteins to form the large latent complex,
which may be sequestered in the extracellular matrix [31].
TGF-1isfoundinmanydifferentcelltypes,butitshighest
concentration is in platelets. As a result, TGF-1 is nor-
mallyreleasedinlargequantitiesfromplateletsatthesiteof
Figure1. TGF-expressioninradiation-inducedlunginjury.
(A): Radiation (RT)-induced lung injury in a rat model. Fi-
scher 344 rats were irradiated to 28 Gy in one fraction to the
right hemithorax and sacrificed at 6 weeks or 6 months after
RT. Slides were stained with either hematoxylin & eosin (top
row) or Masson’s trichrome (bottom row). A nonirradiated
control lung (left column) demonstrates the normal honey-
comb architecture of the lung. At 6 weeks after irradiation
(middle column), one begins to see thickening of the alveolar
walls resulting from edema, corresponding to the inflamma-
tory phase, but with little fibrosis. At 6 months (right column),
there is complete loss of normal alveolar architecture, with ex-
tensive fibrosis (green staining in bottom right panel). Re-
printed from Stone HB, Coleman CN, Anscher MS et al.
Effectsofradiationonnormaltissue:Consequencesandmech-
anisms. Lancet Oncol 2003;4:529–536, with permission from
Elsevier. (B): Fischer 344 rats were irradiated to 28 Gy in one
fraction to the right hemithorax, sacrificed 6 months after ra-
diation, and stained for transforming growth factor (TGF)-1.
There is very little staining for TGF-1 in the control lung
(nonirradiated) in contrast to the irradiated lung, which dem-
onstrates greater expression of TGF-1 in regions of fibrosis.
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tokinearerecruitmentofmonocytesandmacrophagestoan
injury site [32], inhibition of the proliferation of epithelial
cells[33],enhancementofthematurationoffibroblastsinto
postmitotic fibrocytes that increase production of fibrous
tissue [34], promotion of angiogenesis [35, 36], and inhibi-
tion of the breakdown of extracellular matrix [23, 37]. De-
spiteitsroleinnormalwoundhealing,increasedexpression
of TGF-1 has been demonstrated in a number of condi-
tions characterized by excessive fibrosis, including chronic
hepatitis and glomerulosclerosis [24, 38–41]. In addition,
effective treatments for these conditions have been shown
to reduce the development of fibrosis in the affected organ,
withacorrespondingdecreaseintheexpressionofTGF-1
[42–53].
Following exposure to ionizing radiation, the expres-
sion of TGF-1 increased in a dose-dependent manner in
the rat liver [54]. Similarly, in a rat model of radiation-
induced lung injury, fibrosis developed, which was accom-
panied by an increase in TGF-1 expression and activation
of the TGF-1 signal transduction pathway [55, 56]. Fur-
thermore, TGF-1 activation by radiation has been shown
to occur at doses 10 cGy and is roughly proportional to
dose in the range of 10 cGy to 5 Gy [57, 58]. Although ge-
netically engineered loss of TGF-1 expression is a lethal
mutation, knockout mice missing a component of the
TGF-1 signaling pathway (Smad3) are viable, and have
been shown to be resistant to radiation-induced soft tissue
fibrosis [59]. In contrast, humans expressing certain sin-
gle nucleotide polymorphisms in the TGF-1 gene have
been found to be at a higher risk for normal tissue injury
[60]. In animal models of pulmonary fibrosis induced by
bleomycin [52] and in humans exposed to high doses of
chemotherapy in preparation for bone marrow transplanta-
tion who develop pulmonary drug toxicity or hepatic veno-
occlusive disease (Fig. 2), the associated fibrosis is
accompanied by increased expression of TGF-1i na f -
fectedtissues.Thus,thereissubstantialevidenceontheim-
portance of TGF-1 in the development of excessive
fibrosis following exposure to radiation and/or chemother-
apy in both animals and humans.
TGF-1 AS A PREDICTOR OF NORMAL TISSUE
INJURY RISK
Dosing of chemotherapy or radiation is generally based ei-
ther on a prospectively determined maximum-tolerated
dose or, more commonly, in the case of radiation, an em-
pirically determined estimate of the risk for a particular in-
jury developing in a certain percentage of patients within a
defined period of time [1, 2]. In either case, the accepted
tolerancedoseofradiationorchemotherapyproducesdose-
limiting toxicity in a minority of patients, yet it is precisely
these patients that dictate the dose of chemotherapy or ra-
diation for an entire population, when in reality any given
population of patients is likely to contain people who may
be more or less likely to experience toxicity than the “aver-
age” population used to determine dosing guidelines (Fig.
3). Thus, the ability to determine the likelihood of toxicity
foranindividualpatient,ratherthanrelyondosingbasedon
the average sensitivity of a population, is a desirable goal
that should improve the therapeutic ratio (i.e., reduce the
likelihood of toxicity, increase the likelihood of cure, or
both).
In addition to being widely produced throughout the
body, TGF-1 can also be measured in the blood [61]. In-
creased circulating levels of TGF-1 have been found in
patientswithmanydiseases,includingvarioustypesofcan-
cer [62, 63]. Because of the fact that TGF-1 expression in
Figure 2. TGF- expression in chemotherapy-induced liver
injury. Section of normal liver (A) and liver from patient that
died of hepatic veno-occlusive disease after high-dose chemo-
therapy (B).I n(B), evidence of extensive fibrosis around the
central veins (C) is noted (arrow) and there is greater staining
for transforming growth factor 1 (reddish brown areas) im-
mediately adjacent to regions of fibrosis than in the normal
liver in (A). P, portal vein. Reprinted from Anscher MS, Kong
FM, Jirtle RL. The relevance of transforming growth factor
beta 1 in pulmonary injury after radiation therapy. Lung Can-
cer 1998;19:109–120, with permission from Elsevier.
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apy exposure, several researchers have sought to measure
circulating TGF-1 levels in an attempt to predict which
patientsmightbeatanincreasedoradecreasedriskfornor-
mal tissue injury after exposure to chemotherapy or radia-
tion. The first reported study using circulating TGF-1
levelstopredicttheriskfornormaltissueinjurywasbyAn-
scher et al. [61]. Those researchers found, in a group of pa-
tients treated with induction chemotherapy, high-dose
chemotherapy, autologous bone marrow transplant, and in-
volved field radiation for high-risk breast cancer, that
plasma TGF-1 measured after induction chemotherapy
but before high-dose chemotherapy, radiation, or marrow
transplant was strongly correlated with the risk of develop-
ing either pulmonary drug toxicity or hepatic veno-occlu-
sive disease (Fig. 4). Subsequent studies by Anscher and
colleagues, as well as others, have focused on determining
whether TGF-1 could be used in a similar manner to pre-
dict the risk of developing pulmonary injury after radiation
therapy. The results of these studies have been mixed, with
some, but not all, authors finding that TGF-1 levels could
be used to predict the risk for lung injury [64–68]. How-
ever, most of these studies contained small numbers of pa-
tients with relatively few events, thus having little power to
detect differences between study groups [9]. Also, toxicity
endpoints differed (e.g., some considered only symptom-
atic lung injury, whereas others included asymptomatic ra-
diographic changes), as did techniques for measuring
TGF-1 in the blood. A more recent larger pooled analysis
supports the contention that plasma TGF-1 levels can be
used to predict the risk for radiation-induced lung injury
[69]. Additional work is needed to confirm this finding.
In reality, however, because radiation oncologists are
skilled at limiting the volume of normal lung receiving a
highdose,theincidenceofsignificantsymptomaticlungin-
jury (grade 2) in most series is low, and plasma TGF-1
measurements may actually be better suited to determine
patients at low risk for lung injury rather than identifying
those at very high risk [70]. This observation suggests that
plasma TGF-1 measurements might be useful to identify
patients with lung cancer who might be candidates for ra-
diation dose escalation. Anscher et al. [71] tested this hy-
pothesis in a small clinical trial designed to assess the
maximum-tolerated dose of radiation that could be deliv-
ered to the lung using TGF-1 to estimate the risk for dose-
limiting lung toxicity. Patients with locally advanced or
medically inoperable non-small cell lung cancer were
treated with the institutional standard high-dose radiation
approach at the time (1.6 Gy twice daily using a concurrent
boost technique) to a dose of 73.6 Gy. Concurrent chemo-
therapy was not allowed, and the technique included elec-
tive nodal irradiation. TGF-1 was measured at baseline
and after 73.6 Gy. If the TGF-1 level normalized by 73.6
Gy, then the dose was escalated in increments of 6.4 Gy to
successive patients until a dose-limiting toxicity was
Figure3. Alteringdoseonthebasisofanindividualpatient’s
sensitivitytotoxicitycanaffectthetherapeuticratio.Dosingof
chemotherapy or radiation is based on sensitivity to toxicity
thatisbasedonpopulationaverages(solidline).Inreality,any
population also contains individuals that will be either more
sensitive (dashed line) or more resistant (dot-dash line) to
treatment toxicity than the average population. The sensitive
patients, which probably comprise 5%–10% of the overall
population[1,2],nonethelessdrivethedosingschemes.Inthis
example, by holding the acceptable complication incidence at
10%,aresistantpatient(b)couldreceiveanapproximately5%
greaterdosethananaveragepatient(a)anda10%greaterdose
than a sensitive patient. Dose differences of this magnitude
have been associated with differences in outcome.
Figure 4. Correlation of plasma transforming growth factor
(TGF)-1 concentration and the risk for pulmonary drug tox-
icity (PDT) or hepatic veno-occlusive disease (VOD) after
high-dose chemotherapy for advanced breast cancer. Blood
samples were taken from patients after induction chemother-
apy but prior to administration of high-dose chemotherapy
(day 6) and bone marrow transplant. There is a strong corre-
lation between the plasma TGF-1 concentration at day 6
and the risk for either PDT or VOD developing after subse-
quent high-dose chemotherapy. Reprinted from Anscher MS,
Kong FM, Jirtle RL. The relevance of transforming growth
factor beta 1 in pulmonary injury after radiation therapy. Lung
Cancer 1998;19:109–120, with permission from Elsevier.
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could not be escalated beyond 73.6 Gy based on TGF-1
criteria.Intheremainingpatients,eightreceived80Gyand
six received 86.4 Gy. The latter dose was determined to be
the maximally tolerated dose. Thus, this study determined
that it was feasible to use TGF-1 to guide radiation dose
selection for patients with lung cancer. Given the changes
in the treatment approach to lung cancer since that study
was conducted (i.e., ubiquitous use of combined chemora-
diotherapy and increased use of stereotactic radiation ther-
apy for smaller tumors), the study needs to be repeated
using a more current treatment regimen. In a follow-up re-
port, the authors noted that serious long-term toxicity
(grade 3–5) occurred only in the control arm, further sup-
porting the potential of this approach to treatment individ-
ualization [72]. It should be noted, however, that these
higher doses of radiation did not translate into longer sur-
vival. The study was not designed to test this endpoint, and
furtherworkisneededbeforeanyconclusionscanbedrawn
in this regard.
WHY IS TGF-1E LEVATED IN CANCER PATIENTS
EVEN BEFORE TREATMENT BEGINS?
Ashintedatabove,circulatingTGF-1levelsinmanycan-
cer patients are elevated at the time of diagnosis, before
treatment,ascomparedwithpeoplewithoutcancer,andthe
tumor is thought to be the source of TGF-1 [63, 73]. In
addition to contributing to the risk for normal tissue injury
from cancer treatment, TGF-1 also promotes metastasis
[74] and suppresses the immune system [75], so that the
presence of high levels of TGF-1 in cancer patients may
haveanadverseimpactonprognosis[76–78].Animalstud-
ies support this conclusion. For example, in transgenic
mouse models, induction of active TGF- increased the in-
cidence of lung metastases from breast cancer [79],
whereas blocking TGF- activity reduced the metastatic
potential [80]. Recent evidence has also suggested that re-
ceptor tyrosine kinase inhibitors that block the binding of
TGF- to its transmembrane receptors prevent the activa-
tion of the TGF- signaling pathway and reduce the inci-
dence of metastases in a breast cancer model [81]. Also,
tumors that express TGF-1 are more resistant to chemo-
therapy, and sensitivity to cisplatin can be restored with
TGF-1 inhibition [82, 83]. These studies support the ra-
tionale for targeting the TGF- pathway as a potential an-
ticancer therapy.
The reason for the presence of higher levels of TGF-1
in these cancer patients appears to be related to both greater
production and altered bioavailability of this cytokine [84–
86].Kongetal.[62]studiedagroupofwomensuspectedto
have breast cancer on the basis of an abnormal mammo-
gram. In these patients, blood was obtained for cytokine
measurements before and after removal of the tumors by
lumpectomy. Following surgery, there was a significant re-
duction in plasma TGF-1 levels in these patients, suggest-
ing that the tumor was the source of the TGF-1
production. Those authors also studied the tumor speci-
mens using immunohistochemistry to stain for TGF-1 ex-
pressionandinsituhybridizationtolookforthemessageto
producetheTGF-1protein.Incomparisonwithregionsof
normalbreasttissueinthebiopsyspecimens,therewassig-
nificantly greater expression of both messenger RNA and
TGF-1 in the tumor stroma, but not in epithelial cells. As
notedabove,manymalignantepithelialcellslosetheability
to respond to the growth inhibitory effects of TGF-1, and
it appears that the loss of this growth inhibitory feedback
loop leads to increased production of TGF-1 in a futile at-
tempt to stop the proliferation of these malignant epithelial
cells [33, 47, 74, 87, 88]. In terms of bioavailability, the
mannose-6-phosphate/insulin-like growth factor receptor
type II (M6P/IGF2R) plays a critical role in this process
[89].Thegenecodingforthisreceptorhasbeenshowntobe
a tumor suppressor gene [90]. Binding of latent TGF-1t o
M6P/IGF2R facilitates its activation [85], but it also en-
ables the molecule to be presented to lysosomes for degra-
dation [91]. Thus, loss of function of this tumor suppressor
gene could lead to a decreased ability to dispose of latent
TGF-1, which could be activated by other mechanisms
(e.g., free radicals) and lead to an increased risk for normal
tissueinjury.Kongetal.[92]studiedagroupoflungcancer
patients to test this hypothesis. They found that if the
patients had loss of heterozygosity in M6P/IGF2R, and
consequently a nonfunctioning receptor, they were sig-
nificantlymorelikelytohavehigherplasmaTGF-1levels
and to develop radiation-induced lung injury than those
without loss of heterozygosity in the receptor [93]. Thus, it
appears that bioavailability of TGF-1 plays an important
roleintheriskfornormaltissueinjuryinatleastasubsetof
cancer patients.
SUSTAINING THE PHENOTYPE OF NORMAL TISSUE
INJURY AFTER TREATMENT IS COMPLETED
The development of normal tissue injury results from a
complex interplay of contributions to risk from the treat-
ment, the tumor, and the patient (Figure 5). Radiation con-
tributes numerous insults beyond merely dose and volume,
although these two factors no doubt impact the risk for in-
jury. For example, radiation produces free radicals, dam-
ages vasculature, creates a cascade of local and systemic
cytokine and chemokine expression, elicits an inflamma-
tory response, and causes loss of parenchymal cells. Che-
motherapy may increase radiosensitization through various
354 Targeting TGF-1 to Prevent Complicationsmechanisms, lead to parenchymal cell loss, affect DNA re-
pair, suppress the immune system, or cause inflammation.
The tumor itself may lead to architectural destruction, re-
leaseitsowncytokines,affecttheimmunesystem,andalter
vascular permeability. The patient may have underlying
medical conditions predisposing to injury (e.g., diabetes,
poor underlying pulmonary function, or certain collagen
vascular diseases) or have an unknown genetic susceptibil-
ity. All these factors may contribute to a varying degree in
any given patient, and their relative importance cannot as
yet be reliably determined. Nonetheless, it is becoming
clear that abnormal microenvironmental conditions exist
thataresustainedlongafterthebeamisturnedoff,thedrugs
are discontinued, and the tumor is eradicated, which appear
to be responsible for the perpetuation of the tissue atrophy,
loss of parenchymal cells, and excessive fibrosis character-
istic of late normal tissue injury after cancer therapy.
There is increasing evidence that chronic normal tissue
hypoxia develops after exposure to radiation therapy, and
that this phenomenon may be, in part, responsible for sus-
taining the normal tissue injury phenotype [94–96]. Hyp-
oxia has been shown to promote the production of
profibrotic cytokines and stimulate collagen deposition
through the action of TGF-1 [97, 98]. Hypoxia has been
demonstrated after radiation in the lung, central nervous
system, and kidney. It is thought that hypoxia develops as a
result of decreased oxygen delivery resulting from vascular
injury plus greater consumption by activated macrophages
recruited to the site of injury in response to reactive oxygen
species–mediated tissue damage. In the lung, evidence of
sustained oxidative stress and tissue hypoxia have been
demonstrated 6 months after radiation in a rat model, and
this finding was correlated with greater expression and ac-
tivation of TGF-1 and its signaling pathway [95]. West-
bury et al. [99] evaluated a group of patients undergoing
salvage mastectomy for recurrent breast cancer following
radiation therapy. The patients received an injection of the
hypoxic marker pimonidazole prior to surgery. Following
surgery,thenormalbreasttissueinthespecimenswaseval-
uated for the presence of pimonidazole staining, and for the
presenceofthehypoxicmarkercarbonicanhydraseIX(CA
IX). The authors also looked for the presence of radiation
damagehistologically.Intheonlybreastsample(of12)that
showed marked histologic changes consistent with a radia-
tion effect, there was greater staining for pimonidazole, but
not CA IX, suggesting an oxygen tension of 10 mmHg in
this tissue. This is the first in vivo evidence demonstrating
hypoxia in normal irradiated human tissue using this ap-
proach. Given the relationship noted above between hyp-
oxiaandTGF-1,thesedatafurthersupportthecentralrole
of TGF-1 in the development of chronic radiation injury.
THE IMPACT OF TGF-1B LOCKADE ON NORMAL
TISSUE INJURY
The TGF-1 interactome is extremely complex in that
many proteins interact with its transmembrane receptors
and signaling proteins (Smads) within the cytoplasm and
the nucleus, affecting signaling crosstalk and protein tran-
scription [16]. In addition, there is increasing evidence that
some forms of radiation injury may develop via Smad-
independent TGF-1 signaling [100, 101]. The dominant
pathway at this time seems to involve the binding of
TGF-1 to its type II transmembrane receptor. This inter-
action recruits the type I transmembrane receptor to form a
complex with the type II receptor. This complex is phos-
phorylated and activates the signaling proteins Smad2 and
Smad3. These activated Smads bind with Smad4 and are
translocated to the nucleus, where they bind to promoters
and modulate transcription [74]. Given the vast number of
potential targets in this pathway, most work has focused on
interferingwiththebindingofTGF-1toitsreceptors,thus
preventing initiation of the multitude of potential down-
stream interactions. Several approaches have been taken to
preventthebindingofTGF-1toitsreceptor,includingthe
use of anti-TGF-1 antibodies, small molecule receptor ty-
rosine kinase inhibitors, and gene therapy approaches de-
signed to induce production of a soluble TGF-1 type II
receptor. Anscher et al. [96] administered a single dose of
anti-TGF-1 antibody immediately after delivering the fi-
nal fraction of right hemithorax irradiation (40 Gy in five
Figure 5. Potential targets for intervention in the TGF-1
pathway (partial list) [17, 74, 114]. The inactive form of
TGF-1 can be activated through the action of several factors
(green ovals), including ROS, proteases, integrins, and throm-
bospondin-1. The active form of TGF-1 (yellow) can then
signal through either Smad-dependent (light blue) or Smad-
independent pathways (orange, pink, gray). Any point along
these pathways might be targeted by potential inhibitors.
Abbreviations: ERK, extracellular signal–related kinase;
MAPK,mitogen-activatedproteinkinase;mTOR,mammalian
target of rapamycin; PI3K, phosphatidylinositol 3 kinase;
ROS, reactive oxygen species; TGF, transforming growth
factor.
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malsreceivingradiationwithoutantibody,therewassignif-
icantly less fibrosis, TGF-1 expression, and TGF-1-
induced signaling in the animals treated with the antibody.
Ahigherdoseofantibody(1mg/kg)affordedbetterprotec-
tionthandidalowerdose(0.1mg/kg).Thesamegroupalso
tested daily administration of a type I receptor tyrosine ki-
nase inhibitor administered daily to a group of Sprague-
Dawleyratsirradiatedtotherightlung[102].Thedrugwas
administered beginning 7 days prior to irradiation and con-
tinued either for 3 weeks or until sacrifice. Compared with
irradiated animals not receiving the drug, there was signif-
icantly less fibrosis, TGF-1 expression and signaling, and
chronic oxidative stress in the treated groups, with a better
responseseeninthehigh-dosegroup(0.15g/kgversus0.07
g/kg) and in those treated with a long course versus a short
course of therapy. Neither compound has been tested in the
clinic for this purpose.
As stated previously, there is increasing evidence that
TGF-1 signaling through Smad-independent pathways
may stimulate overproduction of fibrous tissue in response
to radiation or chemotherapy. One such pathway signals
through cAbl. The drug imatinib, an inhibitor of the cAbl
pathway in use in the clinic for the treatment of gastrointes-
tinal stromal tumors, was shown to reduce the development
ofpulmonaryfibrosisinresponsetobleomycininananimal
model [53]. TGF-1 was also recently shown to signal
throughtheRho/Rockpathway,independentlyoftheSmad
signal transduction cascade [100, 101]. This pathway has
been implicated in the development of radiation-induced
small intestinal injury. Inhibition of this signaling pathway
has been shown to protect against radiation enteritis.
Other potential approaches target TGF-1 more indi-
rectly, for example, by reducing the stimulus for TGF-1
activation (Fig. 5). Following exposure to radiation, reac-
tive oxygen species are produced [103], and these have
been shown to be capable of activating latent TGF-1 [30].
Mice engineered to overexpress one of the isoforms of su-
peroxide dismutase, an endogenous free radical scavenger,
havebeendemonstratedtoberesistanttoradiation-induced
lung injury [104]. Similarly, administration of superoxide
dismutase mimetics has been shown to reduce the severity
of lung injury in an animal model [105]. Both approaches
resultinlowerexpressionandactivationofTGF-1aswell
asloweractiviationoftheSmad-dependentTGF-1signal-
ing pathway.
As is the case with radiation therapy, targeting the
TGF-1 pathway may be an effective means to prevent or
ameliorate chemotherapy-induced lung injury. Bleomycin-
induced lung injury (Fig. 2) is the classic example of this
toxicity, although newer agents, such as gefitinib, may be
associated with the development of lung injury and fibrosis
[106]. Susceptibility to both radiation- and bleomycin-
induced lung injury in mice may have a common genetic
basis [107]. Bleomycin-induced lung injury in the acute
phases is mediated through the epidermal growth factor re-
ceptor (EGFR) family, most likely human epidermal
growth factor receptor (HER)-2/HER-3 [108]. Blockade of
HER-2/HER-3 signaling ameliorates the development of
pulmonary fibrosis from bleomycin [109]. Because TGF-
may upregulate profibrotic protein expression, in part,
throughanEGFR-mediatedmechanism[110],itshouldnot
be surprising that inhibiting the TGF- pathway also ame-
lioratesthedevelopmentofthistoxicityinanimals[50,111,
112].
In summary, TGF-1 is a critical cytokine responsible
forthedevelopmentoflatenormaltissueinjuryaftercancer
therapy. Monitoring TGF-1 in the plasma and/or screen-
ing for TGF-1 polymorphisms may help to identify pa-
tients at greater or lesser risk for normal tissue injury, but
more work is needed to determine the optimal situations in
which to apply this molecular and genetic information in
theclinic.StrategiestotargetTGF-1clearlyreducethese-
verity of normal tissue injury in animal models. This ap-
proach needs to be tested prospectively in the clinic to
determine if inhibiting the TGF-1 pathway is safe and ef-
fective in humans.
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